1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Functional MR Added To FDA-Approved Indication For Abbott's MitraClip

 
• By Reed Miller

The new indication covers functional mitral regurgitation, also known as secondary mitral regurgitation, which represents two-to-three times as many patients as the primary mitral regurgitation population MitraClip is already labeled for. The approval is supported by results from the COAPT trial, the first randomized trial to show that a mitral-valve repair could improve outcomes in patients with secondary mitral regurgitation.

Vascular-Mitraclip
• Source: Abbott Laboratories, Inc.

US FDA approved Abbott Laboratories Inc.'s MitraClip transcatheter mitral valve repair system for select heart failure patients with clinically significant secondary, or functional, mitral regurgitation based on results of the COAPT trial, the company and agency announced March 14.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation